
|Videos|October 14, 2022
Cabozantinib, Nivolumab, and Ipilimumab: Rationale for Use
Author(s)Rana R. McKay, MD
Dr Rana McKay discusses the rationale for using cabozantinib with nivolumab and ipilimumab in the COSMIC 313 trial and reviews the adverse events seen with this combination in the COSMIC 313 trial.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
4
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
5



















